Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsFRA:01P +0.49%95 Pretax Margin % is 21.44% as of Jun. 2026, which is 21% above its 10-year median of 17.74. GuruFocus rates FRA:01P with a GF Score™ of 95/100 and a GF Value™ of €463.14 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Medpace Holdings ranks better than 90.59% on this metric.
The historical rank and industry rank for Medpace Holdings's Pretax Margin % or its related term are showing as below:
FRA:01P'
s Pretax Margin % Range Over the Past 10 Years
Min: 5.21 Med: 17.74 Max: 22.57
Current: 21.53
FRA:01P's Pretax Margin % is ranked better than 90.59% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.565
vs FRA:01P: 21.53
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Medpace Holdings Pretax Margin % Related Terms
Medpace Holdings Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:01P vs ICLR, RVTY, CRL: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings (FRA:01P) has a Pretax Margin % of 21.44% as of Jun. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Medpace Holdings and its competitors. This is 21% above median its historical median of 17.74. Over the past decade, Medpace Holdings' Pretax Margin % has ranged from 5.21 to 22.57. According to the industry distribution chart, Medpace Holdings ranks #19 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 9.4%.
Is Medpace Holdings' Pretax Margin % too high?
Medpace Holdings' current Pretax Margin % of 21.44% is 21% above median its 10-year median of 17.74. Over the past 10 years, this metric has ranged from a low of 5.21 to a high of 22.57. Based on the distribution chart, Medpace Holdings ranks #19 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Medpace Holdings has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Pretax Margin % compare to ICLR and RVTY?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #19 out of 202 companies for Pretax Margin %. This places Medpace Holdings in the top 9% of its industry — outperforming the majority of peers. Historically, Medpace Holdings' own Pretax Margin % has ranged from 5.21 to 22.57 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Medpace Holdings and its competitors. Medpace Holdings's current Pretax Margin % is 21.44%, which is 21% above median its own 10-year median of 17.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (FRA:01P) is currently considered Modestly Overvalued. The stock's GF Value™ is €463.14, compared to a current price of €530.40 — trading 14.5% above its estimated fair value. The current Pretax Margin % is 21.44%, which is 21% above median its 10-year median of 17.74. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Medpace Holdings (FRA:01P), the current Pretax Margin % is 21.44% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (FRA:01P) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of €530.40 is trading 14.5% above its estimated GF Value™ of €463.14.
GuruFocus considers Medpace Holdings to be Modestly Overvalued.
Key valuation signals for FRA:01P:
Pretax Margin %: 21.44% (21% above median its 10-year median of 17.74)
GF Value™: €463.14 vs. price of €530.40 (14.5% above fair value)
No single metric tells the full story. See the FRA:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score
Get the complete analysis for FRA:01P
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:01P has been successfully added to your 
